Total Funding
78
84
Total FundingGrant raised
Growth Score
-7 pts
Heat Score
-8 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
32394
Reconnect Labs develops next-gen psychedelic medicines for neuropsychiatry.
- Daniel Claussen: Chief Business Officer & Co-Founder
- Dario Dornbierer: Co-Founder & CSOPast Role: University of Zurich, SNF Bridge Poc Fellowship
About the Company
Reconnect Labs is a clinical stage biopharmaceutical company specializing in neuropsychiatry. The company focuses on the development of next-generation psychedelic medicines. Utilizing Swiss precision design, Reconnect Labs aims to address unmet medical needs in mental health through innovative small molecule drugs. The company is involved in
multiple clinical trials and leverages a robust technology platform to advance its therapeutic pipeline.
